This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In newly diagnosed average and high standard risk B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improved disease-free survival (DFS) by approximately 97.5% and 94.1%, respectively.
Glucagon-like peptide 1 (GLP1) receptor agonists were shown to be associated with a reduced risk of venous thromboembolism (VTE), while high dietary fiber intake was shown to enhance microbiome health, lower graft-versus-host disease (GVHD) severity, and improve overall survival following allogeneic hematopoietic cell transplantation.
(This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions, sign up here.) Greetings from the always-lovely San Diego. Adam Feuerstein, here, and as you can see from the sunrise photo above, I am still very much on East Coast time. (Nice view from my hotel room, however.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
A ketogenic diet and its key metabolite, -hydroxybutyrate, enhance the efficacy of CAR T-cell therapy by improving metabolic fitness, cytokine production, and cellular expansion, offering a promising, safe strategy for optimizing cancer immunotherapy.
First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
Rakesh Popat, MBBS, PhD explains the mechanisms of action behind the improvement in minimum residual disease in patients with lenalidomide-refractory multiple myeloma with cilta-cel compared with standard of care.
52
52
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Rakesh Popat, MBBS, PhD explains the mechanisms of action behind the improvement in minimum residual disease in patients with lenalidomide-refractory multiple myeloma with cilta-cel compared with standard of care.
The King Kong of weight loss drugs will be available on the NHS but only patients with most need will get it Mounjaro, known as the King Kong of weight loss drugs, will be available to patients on the NHS, but this week it was announced the medication will be prioritised to people with the highest needs with the rollout expected to extend over 12 years.
Amir Ali, PharmD, BCOP highlights the success of shorter-treatment duration venetoclax in patients with acute myeloid leukemia and efficacy of pre-transplant blinatumomab in those with acute lymphocytic leukemia.
On December 1, 2024, Biocon announced that the FDA has approved YESINTEK (ustekinumab-kfce), a biosimilar to J&Js STELARA. YESINTEK is approved for the treatment of Crohns disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis. According to the announcement, Biocon had entered into a settlement and licensing agreement with Janssen to commercialize YESINTEK in the United States no later than February 22, 2025, upon approval from the FDA.
Jason Wang, MD highlights the reduction in incidence and severity of adverse events such as cytokine release syndrome and ICANS following axi-cel treatment in patients with R/R LBCL.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content